Related Links

• Next-generation Aminoglycosides
• LpxC
• Additional Programs/Inlicensing Interests

Despite a clear and growing medical need, the pipeline for new antibiotics is drying up. FDA approvals of new antibacterial agents have decreased 56% since 1983 as several large pharmaceutical companies have exited the space, and virtually no agents are in the clinical pipeline for the treatment of resistant Gram-negative pathogens (Spellberg et al., Clinical Infectious Diseases, 2004, 38, 1279.). Achaogen has numerous scientific programs addressing this critical unmet medical need.

The drug development process for antibacterials remains attractive, as antibacterials have a significantly higher clinical success rate than products in other therapeutic areas. Preclinical in vitro and in vivo efficacy models have excellent predictive value for clinical outcomes, greatly enhancing the potential for our preclinical programs to yield commercially relevant therapeutics that receive regulatory approval. Moreover, antibacterial clinical trials are relatively short and typically involve unambiguous quantitative endpoints.